SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a ...
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- QuEra Computing, the leader in neutral-atom quantum computing, today announced that all three research projects in which QuEra is involved have advanced to ...
The half-life of CK-586 was observed to be in the range of 14 to 17 hours. The data support the advancement of CK-586 to a Phase 2 trial for heart failure with preserved ejection fraction, expected to ...
(RTTNews) - Cytokinetics (CYTK) presented data from the Phase 1 study of CK-4021586, or CK-586. The study met its primary and secondary objectives to assess the safety, tolerability and ...
PALO ALTO, Calif.--(BUSINESS WIRE)--PsiQuantum today announced that it was awarded a contract with the Defense Advanced Research Projects Agency (DARPA) to continue work on the Underexplored Systems ...
HOBOKEN, N.J., Dec. 17, 2024 /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (Nasdaq: QUBT), an innovative, integrated photonics and quantum optics technology company, today announced ...
PALO ALTO, Calif.--(BUSINESS WIRE)--PsiQuantum has successfully completed the research & development viability phase of the Defense Advanced Research Projects Agency's (DARPA) Underexplored Systems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback